Why Celcuity Stock Was a Winner on Wednesday
Key Points
This is a breast cancer treatment, Revtorpyk.
It was approved by the FDA in July.
- 10 stocks we like better than Celcuity ›
On a generally forgettable Wednesday for the stock market, with many titles dropping in value, Celcuity (NASDAQ: CELC) stood out by posting a gain. Investors bought into the company, which is moving from the clinical to the commercial stage with the launch of its first regulator-approved product. Celcuity's stock closed 2.8% higher, on a day when the S&P 500 index slid by 0.3%.
The inaugural commercial launch
Celcuity, a biotech focused on cancer treatments, announced that its Revtorpyk is now commercially available for eligible patients in the U.S. The drug received Food and Drug Administration (FDA) approval in July for certain forms of breast cancer.
Missed AI’s "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our analysts, we’re only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »
Image source: Getty Images.
The company added that it has also launched Revtorpyk Support Services, a program that provides financial support and other services to both physicians and patients.
Celcuity said that breast cancer is the second most common cancer, with over two million cases diagnosed around the world in 2022. HR+/HER2 breast cancer, the type Revtorpyk is indicated for, comprises roughly 70% of all instances of the disease.
The market will decide
Since this affliction is so widespread, any weapon in the fight against it is sure to be put to good use.
Celcuity's first commercialized drug should be a success, so it's little wonder investors were eager to buy its equity on Wednesday (although the launch was largely priced into the stock). Now it'll be crucial for investors to monitor how well Revtorpyk does in the market.
Should you buy stock in Celcuity right now?
Before you buy stock in Celcuity, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Celcuity wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $379,123!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,396,103!*
Now, it’s worth noting Stock Advisor’s total average return is 933% — a market-crushing outperformance compared to 212% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of September 30, 2026.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
